2024³â04¿ù29ÀÏmon
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
´º½ºÈ¨ > ¾ÆÄ«µ¥¹Ì

ÃøµÎ°ñ ÀÚ±â°ø¸í¿µ»ó¿¡¼­ ¿Í¿ì½Å°æ ÀúÇü¼ºÁõ ¶Ç´Â ¹«Çü¼ºÁõÀÌ ÀǽɵǴ ±Í¿¡ ½ÃÇàÇÑ

¸ñÀûÀΰø¿Í¿ìÀ̽ļú Àü, ¿Í¿ì½Å°æÀÇ ÇغÎÇÐÀû, ±â´ÉÀûÀÎ È®ÀÎÀÌ ÇÊ¿äÇÏ´Ù. ¼øÀ½Ã»·Â°Ë»ç¿Í û¼º³ú°£¹ÝÀÀ °Ë»ç»ó ¹ÝÀÀÀÌ ¾ø°í ÀÚ.2006-11-21 00:48:35

Chemotherapy-related Arthropathy

ABSTRACTPurpose: Rheumatic manifestations may develop in patients who receive chemotherapy. We examined the characterist2006-10-23 01:32:50

ô¼ö¼Õ»ó ȯÀÚÀÇ È£ÈíÀçÈ°

ô¼ö¼Õ»ó ȯÀÚÀÇ Àü¹ÝÀûÀÎ »ç¸Á·üÀº °¨¼ÒÇÏ¿´Áö¸¸ È£Èí±â°è ÇÕº´ÁõÀÇ ¹ß»ý·ü°ú ÀÌ·Î ÀÎÇÑ »ç¸Á·üÀº ¾ÆÁ÷µµ ³ô´Ù. ô¼ö¼Õ»ó ȯÀÚ.2006-10-15 16:02:22

õ½Ä¿¡¼­ Ç÷°ü³»ÇǼºÀåÀÎÀÚ(vascular endothelial growth factor)ÀÇ matrix metallopr

±â°üÁö õ½ÄÀº TH2 ¼¼Æ÷¿¡ ÀÇÇÑ ±âµµ ¿°Áõ°ú ±âµµ °³ÇüÀ» Ư¡À¸·Î ÇÏ´Â ±âµµÀÇ ¸¸¼º ¿°Áõ¼º ÁúȯÀÌ´Ù. ±âµµ °³ÇüÀº ±âµµÀÇ ¸¸¼º2006-10-08 17:53:35

Gene expression signatures associated with the resistance to imatinib

¹«Á¦ ¹®¼­Gene expression signatures associated with the resistance to imatinib Y-J Chung 1 , 6 , T-M Kim 1 , 6 , D-W Kim2006-09-28 01:58:42

Çѱ¹Çü õ½ÄÄ¡·á Áöħ, EAMÀÇ °³¹ß ¹è°æ°ú ÀÇÀÇ

ÃÖ±Ù ±Þ¼ÓÇÑ »ê¾÷È­·Î ÀÎÇÑ ´ë±â¿À¿°, ¾Ë·¹¸£±â ¿øÀι°ÁúÀÇ Áõ°¡ µî »ýȰȯ°æÀÇ º¯È­·Î õ½ÄÀÇ À¯º´·üÀº ±Þ¼ÓÈ÷ Áõ°¡ÇÏ°í ÀÖ´Ù. 2006-09-24 12:53:19

Çѱ¹ÀÎ ÀÌ¿µ¾çÇü ¼öÆ÷¼ºÇ¥Çǹڸ®Áõ ȯÀÚ¿¡¼­ÀÇ Á¦ VIIÇü Äݶó°Õ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ ºÐ¼®

ÀÌ¿µ¾çÇü ¼öÆ÷¼ºÇ¥Çǹڸ®Áõ(dystrophic epidermolysis bullosa, ÀÌÇÏ DEB)Àº Á¦ VIIÇüÄݶó°ÕÀÇ À¯ÀüÀÚÀÎ COL7A1ÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇ2006-09-17 10:10:13

CagA-Producing Helicobacter pylori and Increased Risk of Gastric Cancer

CagA-Producing Helicobacter pylori and Increased Risk of Gastric Cancer: A Nested Case-Control Study in KoreaJin Gwack,12006-09-11 10:07:19

´ç´¢ ºñ¸¸È¯ÀÚ¿Í ´Ü¼ø ºñ¸¸ÀÚ°£ ÀÓ»ó¾ç»ó Â÷ÀÌ

ÃÖ±Ù ¿µµ¿¼¼ºê¶õ½º ³»ºÐºñ³»°úÀÇ ¾Èö¿ì ±³¼öÆÀÀº ¹Ì±¹ºñ¸¸ÇÐȸ¿¡¼­ ¹ßÇàÇÏ´Â ±ÇÀ§ÀÖ´Â ±¹Á¦ÇмúÁöÀÎ Obesity¿¡ ´ÙÀ½°ú °°Àº ³í.2006-09-01 06:02:39

..[11][12][13][14]
¸íÁöº´¿ø, ͺ ÀÌ°ÇÈñ ȸÀå ÁÖÄ¡ÀÇ ÀÌ°­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçÈ°ÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇÑ°ñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàÇ°±¤°í½ÉÀÇÀ§¿øȸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾Æû¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇÑ°ñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈÄ°ú), ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó